Finance

Lists
Why is BBOT down 2,78%?
Dive Deeper
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
3,50 US$
-2,78%
(-0,100) 1D
3,49 US$
-0,29% (-0,0100)
After hours
Closed: 6 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
3,60 US$
High
3,72 US$
Low
3,48 US$
Mkt. cap
303,21 მლნ.
Avg. vol.
647,50 ათ.
Volume
658,95 ათ.
52-wk high
14,87 US$
52-wk low
3,48 US$
EPS
-3,04 US$
Shares outstanding
80,17 მლნ.
No. of employees
88
Open
3,60 US$
High
3,72 US$
Low
3,48 US$
Mkt. cap
303,21 მლნ.
Avg. vol.
647,50 ათ.
Volume
658,95 ათ.
52-wk high
14,87 US$
52-wk low
3,48 US$
EPS
-3,04 US$
Shares outstanding
80,17 მლნ.
No. of employees
88
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersSouth San Francisco, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitebbotx.com
Analyst ratings
Based on 9 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current 3,50 US$
25,00 US$ (+614,29%)
Average
21,00 US$ (+500,00%)
Lowest
15,00 US$ (+328,57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Berens
Leerink Partners
Buy
Reiterated
25,00 US$
+614,3%
09/18/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Unknown Analyst
Wedbush
Buy
Maintained
25,00 US$
+614,3%
09/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
21,00 US$
+500%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
22,00 US$
+528,6%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
15,00 US$
+328,6%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
20,00 US$
+471,4%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
18,00 US$
+414,3%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
25,00 US$
+614,3%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
22,00 US$
+528,6%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
25,00 US$
+614,3%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
22,00 US$
+528,6%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
29,00 US$
+728,6%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35,05 მლნ.
38,07 მლნ.
39,80 მლნ.
49,22 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14,13 მლნ.
5,33 მლნ.
6,38 მლნ.
10,96 მლნ.
Operating expense
49,18 მლნ.
43,41 მლნ.
46,18 მლნ.
60,19 მლნ.
Total operating expenses
49,18 მლნ.
43,41 მლნ.
46,18 მლნ.
60,19 მლნ.
Operating income
-49,18 მლნ.
-43,41 მლნ.
-46,18 მლნ.
-60,19 მლნ.
Other non operating income
980,00 ათ.
187,00 ათ.
129,00 ათ.
182,00 ათ.
EBT including unusual items
-44,76 მლნ.
-38,80 მლნ.
-42,11 მლნ.
-56,45 მლნ.
EBT excluding unusual items
-44,76 მლნ.
-38,80 მლნ.
-42,11 მლნ.
-56,45 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44,76 მლნ.
-38,80 მლნ.
-42,11 მლნ.
-56,45 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-1,03
-0,49
-0,53
-0,71
Interest and investment income
3,44 მლნ.
4,42 მლნ.
3,94 მლნ.
3,55 მლნ.
Interest expense
-
-
-
-
Net interest expenses
3,44 მლნ.
4,42 მლნ.
3,94 მლნ.
3,55 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-49,11 მლნ.
-43,32 მლნ.
-46,10 მლნ.
-60,11 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები